Research

From left, Kimryn Rathmell, MD, PhD, Bradley Reinfeld, Matthew Madden and Jeffrey Rathmell, PhD, have discovered that immune cells — not cancer cells — are the major glucose consumers in the tumor microenvironment, upending a century-old observation.
April 7, 2021

Study revises understanding of cancer metabolism

Tumors consume glucose at high rates, but a team of Vanderbilt researchers has discovered that cancer cells themselves are not the culprit, upending models of cancer metabolism that have been developed and refined over the last 100 years.

By Leigh MacMillan
April 1, 2021

COVID-19 met with intensive teamwork

Team members serving COVID-19 inpatients were more densely connected, interacting far more than their medical ICU counterparts.

By Paul Govern
April 1, 2021

Novel way to neutralize Rift Valley Fever Virus

The discovery of monoclonal antibodies that neutralize Rift Valley Fever Virus — an emerging infection with pandemic potential — lays the foundation for future therapeutic antibody development.

By Bill Snyder
Deanna Edwards, PhD, left, Jin Chen, MD, PhD, and colleagues are studying a new therapeutic strategy for triple-negative breast cancer.
April 1, 2021

Breast cancer cells ‘steal’ nutrients from immune cells: study

Triple-negative breast cancer cells engage in a “glutamine steal” — outcompeting T cells for the nutrient glutamine and impairing their ability to kill tumor cells, Vanderbilt researchers have discovered.

By Leigh MacMillan
April 1, 2021

Study shows new COVID target could improve vaccines

Despite an impressive vaccination effort that exceeds 2 million shots a day, rates of COVID-19 are again on the rise in several parts of the United States, as is the spread of highly transmissible variants of the virus.

By Bill Snyder
March 25, 2021

Forty-three percent of melanoma patients have chronic complications from immunotherapies

Chronic side effects among melanoma survivors after treatment with anti-PD-1 immunotherapies are more common than previously recognized, according to a study published March 25 in JAMA Oncology.

By Tom Wilemon
March 25, 2021

Team studies new use for pulmonary hypertension drug

An FDA-approved medication enhances the function of T regulatory cells (Treg), a class of immune cells that restrains the immune response, Vanderbilt investigators have discovered.
By Leigh MacMillan
March 23, 2021

Prostate cancer microenvironment

Distinct cancer-associated fibroblasts in the prostate tumor microenvironment may influence tumor progression and could point to new therapeutic targets.
By Leigh MacMillan
March 22, 2021

Chemo for cancer lowers dementia risk

Cancer chemotherapy lowered risk of Alzheimer’s disease and other neurocognitive disorders that disproportionately affect older people.
By Paul Govern
March 18, 2021

Strength training for osteoarthritis

High-intensity strength training is not more effective than low-intensity training or educational efforts for reducing knee pain in patients with osteoarthritis.
By Emily Stembridge
March 18, 2021

HIV, diabetes and immune cells in fat

In HIV-positive individuals with diabetes, immune cells in fat are more proinflammatory and cytotoxic and may represent a therapeutic target for diabetes.
By Leigh MacMillan
March 18, 2021

Study to assess allergic reactions to COVID vaccines

Vanderbilt University Medical Center is recruiting volunteers for a randomized controlled phase 2 clinical trial to help determine the prevalence of systemic allergic reactions (SARS) to the two-dose COVID-19 mRNA vaccines made by Pfizer-BioNTech and Moderna.
By Bill Snyder
March 18, 2021

Vanderbilt research played key role in new lung screen guidelines

The U.S. Preventive Services Task Force (USPSTF) has formally recommended two changes that will nearly double the number of people eligible for lung cancer screening by lowering the age from 55 to 50 and reducing the number of smoking history pack years from 30 to 20.
By Tom Wilemon
1 … 55 56 57 58 59 … 126